Hepion Pharmaceuticals Receives $3.2 Million in Aggregate Non-Dilutive Funding

Approximately $2.9 Million from Sale of Its New Jersey State Net Operating Losses (“NOLs”), Plus $0.3 Million from Alberta Innovation Employment Grant